Travere Therapeutics moved to expand its rare-disease kidney pipeline, signing a global licensing deal with Everest Medicines for civorebrutinib, a covalent reversible BTK inhibitor. The transaction is valued at $1.14 billion, with $112.5 million upfront and up to about $1.03 billion in milestone payments tied to development, regulatory, and commercial targets across as many as five indications. The asset has proof-of-concept clinical evidence in primary membranous nephropathy, and the company is positioning it for additional immune-mediated rare kidney diseases, including immune-mediated FSGS and minimal change disease. Travere said it plans to work with Everest and regulators to define next-stage development after closing. Mechanistically, Travere emphasized that civorebrutinib forms a reversible covalent bond with BTK, positioning it differently from currently marketed irreversible covalent BTK inhibitors and non-covalent reversible options. The deal underscores continued industry focus on immune-pathway modulation in rare kidney indications, where biomarker-driven patient selection and careful regulatory sequencing will likely determine how quickly civorebrutinib can differentiate.